Partnering and Business Opportunities:
If interested in any of these projects, please contact Mahima Agochiya, Business Development Manager of SPARK
Novel, less toxic aminoglycoside antibiotic based on new understanding of toxicity. Leads show broad-spectrum antimicrobial activity and substantially less ototoxicity and nephrotoxicity in animals.
Novel broadly-protective influenza vaccine. Currently optimizing protein folding and developing a cold-chain independent production scheme. Plan ferret testing within a year.
Novel target to treat heart failure through agonist activity. Proof-of-concept animal studies supported link between target signaling and cardiac function.
Diagnostic predictor for risk of Kawasaki Disease in children for use in combination with in silico tool. Validating biomarkers in patient samples.
Small molecule inducer of melanin production/tanning response as therapy for xeroderma pigmentosum (XP), vitiligo, erythropoietic protoporphyria (EPP).
A minimally invasive diagnostic method to detect intestinal mucosal injury related to inflammatory bowel diease or necrotizing enterocolitis. An ELISA based assay development is currently underway for selected biomarkers.
|Gene Therapy||Gene/Cell Therapy||sk10134||
Innovative platform to enhance Adeno-associated virus (AAV)-based gene therapy. Identified a host factor to improve AAV infection for all serotypes and cell types.
|Hematology, Immunology||Antibiotic, Gene/Cell Therapy||sk08095||
Therapeutic monoclonal antibody to treat acute graft versus host disease (GVHD) (orphan disease).
Small molecule inducer of beta cell regeneration for treatment of type 2 diabetes. Lead compound optimization on-going.
Novel targets for induction of brown fat from white fat to treat obesity. Preparing high-throughput screening to identify small molecule inhibitors.
Inexpensive, point-of-care diagnostic to measure chemotherapy-induced hyperammonemia (“chemo brain”) and inborn errors of ammonia metabolism.
Repurposed small molecule to prevent cancer emergence in patients with inherited BRCA-1 mutants (orphan disease). Establishing biomarkers and in consultation with FDA about trial endpoints. Good drug safety record, but never approved in USA.
Topical formulation of a small molecule to prevent radiation-induced dermatitis and xerostomia
|Platform||Gene/Cell Therapy, Vaccine||sk12158||
Charge –Altering Releasable Transporters (CARTS): New materials enable a new platform technology for gene delivery, vaccinations, and cancer immunotherapy